Evolent Health, Inc (EVH): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVH POWR Grades
- Growth is the dimension where EVH ranks best; there it ranks ahead of 99.98% of US stocks.
- The strongest trend for EVH is in Stability, which has been heading down over the past 178 days.
- EVH's current lowest rank is in the Quality metric (where it is better than 11.08% of US stocks).
EVH Stock Summary
- Price to trailing twelve month operating cash flow for EVH is currently 144.32, higher than 97.52% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of 58.17%, EVOLENT HEALTH INC's debt growth rate surpasses 82.38% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, EVOLENT HEALTH INC is reporting a growth rate of 128.43%; that's higher than 88% of US stocks.
- Stocks that are quantitatively similar to EVH, based on their financial statements, market capitalization, and price volatility, are DNUT, BRP, VITL, SHEN, and NEGG.
- EVH's SEC filings can be seen here. And to visit EVOLENT HEALTH INC's official web site, go to www.evolenthealth.com.
EVH Valuation Summary
- EVH's price/sales ratio is 2.3; this is 0% higher than that of the median Technology stock.
- EVH's price/sales ratio has moved NA NA over the prior 91 months.
Below are key valuation metrics over time for EVH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EVH | 2022-11-25 | 2.3 | 3.3 | -207.4 | -72.7 |
| EVH | 2022-11-23 | 2.3 | 3.3 | -208.1 | -72.9 |
| EVH | 2022-11-22 | 2.3 | 3.2 | -206.5 | -72.4 |
| EVH | 2022-11-21 | 2.2 | 3.2 | -201.4 | -70.8 |
| EVH | 2022-11-18 | 2.3 | 3.2 | -205.7 | -72.1 |
| EVH | 2022-11-17 | 2.0 | 2.8 | -179.3 | -63.9 |
EVH Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at -109.08%.
- Its 4 year net cashflow from operations growth rate is now at -5.54%.
- Its year over year net cashflow from operations growth rate is now at 167.21%.
The table below shows EVH's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1,217.939 | 19.408 | -13.462 |
| 2022-06-30 | 1,087.825 | 67.379 | -28.625 |
| 2022-03-31 | 989.943 | 29.468 | -33.144 |
| 2021-12-31 | 907.957 | 38.747 | -37.601 |
| 2021-09-30 | 931.522 | -40.76 | -46.579 |
| 2021-06-30 | 973.644 | -105.76 | -70.887 |
EVH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EVH has a Quality Grade of D, ranking ahead of 14.15% of graded US stocks.
- EVH's asset turnover comes in at 0.713 -- ranking 221st of 563 Business Services stocks.
- EVOL, GLOB, and AKAM are the stocks whose asset turnover ratios are most correlated with EVH.
The table below shows EVH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.713 | 0.254 | -0.052 |
| 2021-06-30 | 0.726 | 0.244 | -0.113 |
| 2021-03-31 | 0.742 | 0.245 | -0.547 |
| 2020-12-31 | 0.746 | 0.228 | -0.601 |
| 2020-09-30 | 0.704 | 0.220 | -0.869 |
| 2020-06-30 | 0.636 | 0.223 | -0.795 |
EVH Price Target
For more insight on analysts targets of EVH, see our EVH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $28.33 | Average Broker Recommendation | 1.43 (Moderate Buy) |
EVH Stock Price Chart Interactive Chart >
EVH Price/Volume Stats
| Current price | $26.91 | 52-week high | $39.78 |
| Prev. close | $27.59 | 52-week low | $21.36 |
| Day low | $26.75 | Volume | 1,107,000 |
| Day high | $27.80 | Avg. volume | 931,557 |
| 50-day MA | $30.72 | Dividend yield | N/A |
| 200-day MA | $30.94 | Market Cap | 2.72B |
Evolent Health, Inc (EVH) Company Bio
Evolent Health provides health-care delivery and payment solutions in the United States. The company was founded in 2011 and is based in Arlington, Virginia.
Latest EVH News From Around the Web
Below are the latest news stories about EVOLENT HEALTH INC that investors may wish to consider to help them evaluate EVH as an investment opportunity.
This Analyst Is Bullish On Evolent Health's Recent Deal, Calls 'Highly Strategic Acquisition'Thursday after close, Evolent Health Inc (NYSE: EVH) agreed to acquire Magellan Specialty Health, the specialty benefit management organization owned by Centene Corporation (NYSE: CNC), for $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance. William Blair is positive on the acquisition and believes this is consistent with management's prior commentary that Evolent would consider strategic assets that fit under the specialty care man |
Why Evolent Health Stock Is Soaring TodayShares of Evolent Health (NYSE: EVH) were soaring 14% higher as of 10:47 a.m. ET on Friday. The big gain came after the company announced the day before that it plans to acquire NIA (also known as Magellan Specialty Health) from Centene (NYSE: CNC). NIA helps healthcare organizations manage costs and improve quality in several specialty areas. |
Centene Agrees To Divest Magellan Specialty Health To Evolent HealthEvolent Health Inc (NYSE: EVH) has agreed to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene Corporation (NYSE: CNC). The organization focuses on managing cost and quality in radiology, musculoskeletal, physical medicine, and genetics. Deal consideration includes $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance. The upfront consideration will be partly funded by |
Clayton-based Centene to sell a specialty benefit management business for $750M in latest divestureThe announcement is the latest in a flurry of deals in which Centene, a Clayton-based provider of managed care for government-sponsored health plans, has sold chunks of its business this year. |
Centene agrees to sell benefit-management unit to Evolent Health for $750 millionCentene Corp. said late Thursday it has agreed to sell its Magellan Specialty Health benefit-management business to Evolent Health Inc. for $750 million, lauding it as a "milestone" in the health insurer's "value creation program and ongoing portfolio review." Centene bought Magellan Specialty Heath in January as part of its acquisition of Magellan Health, Inc. Upon the deal's closing, Centene and Evolent plan to launch a national multi-year partnership, the company said. "By combining Magellan |
EVH Price Returns
| 1-mo | -16.25% |
| 3-mo | -26.78% |
| 6-mo | -11.97% |
| 1-year | 3.26% |
| 3-year | 273.23% |
| 5-year | 109.42% |
| YTD | -2.75% |
| 2021 | 72.61% |
| 2020 | 77.13% |
| 2019 | -54.64% |
| 2018 | 62.20% |
| 2017 | -16.89% |
Continue Researching EVH
Want to do more research on Evolent Health Inc's stock and its price? Try the links below:Evolent Health Inc (EVH) Stock Price | Nasdaq
Evolent Health Inc (EVH) Stock Quote, History and News - Yahoo Finance
Evolent Health Inc (EVH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...